NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”). While the results showed overall improvement in patients treated with the Company’s proprietary cells, the magnitude of the effect and the perceived trend of the effect over time did not justify continuing the study or exploring the variability in the initial patient observations, given the financial resources available to the Company.
- Two Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board
- Get registered for Working 2 Walk 2017 today!
- Airline lobby wins another big delay on reporting data for wheelchair damages and losses *January 2019*
- An injectable hydrogel enhances tissue repair after spinal cord injury by promoting extracellular matrix remodeling
- 17th International Symposium on Neural Regeneration
- Combinatory repair strategy to promote axon regeneration and functional recovery after chronic spinal cord injury
- Gait Rehabilitation with a Neurologically Controlled Exoskeleton
- Nanoparticles limit damage in spinal cord injury
- It’s Not a Rat’s Race for Human Stem Cells Grafted to Repair Spinal Cord Injuries
- It’s On! U2FP Working 2 Walk 2017 and SCI Curecast Episode 11
- InVivo Therapeutics restructures and suspends chronic SCI stem cell and gene therapy research programs
- Pretreatment May Unlock the Regenerative Potential of Neural Stem Cells in Chronic Spinal Cord Injury
- Regulateable Chondroitinase ABC gene therapy as a treatment for spinal cord injury
- Miracle chemical ‘cocktail’ could cure spinal cord damage
- Combined expression of pro-regenerative transcription factors and transplanted stem cells to promote corticospinal tract regeneration.
Follow on TwitterMy Tweets